Printer Friendly

BIOGEN APPOINTS JOHN CONLEY AND MARK LEUCHTENBERGER AS DIRECTORS OF MARKETING

 CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) announced today the appointments of John Conley and Mark Leuchtenberger to the newly created positions of directors of marketing. Conley's areas of responsibilities include Hirulog(TM), Biogen's proprietary direct thrombin inhibitor, other cardiovascular and infectious disease programs and market research. Leuchtenberger is responsible for the marketing and business development of Biogen's interferon and inflammation programs. They report to Kenneth M. Bate, vice president-marketing and sales.
 Conley joined Biogen in 1989 as a product manager for cardiovascular programs. He recently served as group product manager for Biogen's cardiovascular and inflammation development programs. Before joining Biogen, Conley was a manager for Bain and Company. He holds a B.S. in Economics from the University of Pennsylvania and a Master's degree from the Yale School of Management.
 Leuchtenberger joined Biogen in 1990 as a Market Development Manager and was promoted to product manager in 1992. Prior to joining Biogen, he was a consultant for Bain & Company. Leuchtenberger graduated from Wake Forest University and holds a Master's degree from the Yale School of Management.
 Biogen, Inc., headquartered in Cambridge, Mass. is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, and other cancers and viruses.
 -0- 9/17/93
 /CONTACT: Kathryn R. Bloom, director of communications, 617-252-9851 (media); or Michelle A Payette, communications assistant, 617-252-9837 (media); or Amy S. Hedison, director, investor relations, 617-252-9873 (investor), all of Biogen/
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER

CM-DJ -- NE002 -- 2967 09/17/93 09:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1993
Words:301
Previous Article:LTX CORPORATION ANNOUNCES PROFITABLE FOURTH QUARTER
Next Article:WOOLWORTH CORPORATION TO ACQUIRE ACCESSORY LADY CHAIN
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters